Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GoHealth (GOCO) Research & Development (2019 - 2025)

GoHealth (GOCO) has disclosed Research & Development for 7 consecutive years, with -$60.2 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 167.14% to -$60.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$33.0 million through Dec 2025, down 114.83% year-over-year, with the annual reading at $34.9 million for FY2025, 84.31% down from the prior year.
  • Research & Development hit -$60.2 million in Q4 2025 for GoHealth, down from $10.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $285.9 million in Q4 2021 to a low of -$90.7 million in Q4 2023.
  • Historically, Research & Development has averaged $32.7 million across 5 years, with a median of $12.4 million in 2021.
  • Biggest five-year swings in Research & Development: skyrocketed 1401.64% in 2021 and later plummeted 240.12% in 2023.
  • Year by year, Research & Development stood at $285.9 million in 2021, then plummeted by 77.35% to $64.8 million in 2022, then tumbled by 240.12% to -$90.7 million in 2023, then soared by 198.84% to $89.7 million in 2024, then tumbled by 167.14% to -$60.2 million in 2025.
  • Business Quant data shows Research & Development for GOCO at -$60.2 million in Q4 2025, $10.0 million in Q3 2025, and $8.2 million in Q2 2025.